ストックスクリーナーアプリを入手
25.60
1.83%
0.46
プレマーケット:
25.98
0.38
+1.48%
前日終値:
$25.14
開ける：
$25.6
24時間の取引高:
1.16M
Relative Volume:
1.75
時価総額：
$1.79B
収益：
-
当期純損益:
$-237.22M
株価収益率:
-6.7725
EPS:
-3.78
ネットキャッシュフロー:
$-212.64M
1週間 パフォーマンス:
+17.06%
1か月 パフォーマンス:
-12.75%
6か月 パフォーマンス:
-4.33%
1年 パフォーマンス:
+16.84%
1日の値動き範囲:
$25.25
$26.20
1週間の範囲:
$21.97
$26.20
52週間の値動き範囲:
$15.32
$37.00
Akero Therapeutics Inc Stock (AKRO) Company Profile
名前
Akero Therapeutics Inc
セクター
電話
650-487-6488
住所
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
AKRO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
25.60 | 1.79B | 0 | -237.22M | -212.64M | -3.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-18 | 開始されました | Citigroup | Buy |
| 2024-04-22 | 再開されました | BofA Securities | Neutral |
| 2023-09-19 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-08-28 | 開始されました | UBS | Buy |
| 2023-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-14 | アップグレード | Evercore ISI | In-line → Outperform |
| 2021-10-19 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-10 | 開始されました | BofA Securities | Buy |
| 2021-02-26 | 開始されました | Guggenheim | Buy |
| 2020-09-10 | 開始されました | Morgan Stanley | Overweight |
| 2020-07-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-07 | 開始されました | Chardan Capital Markets | Buy |
| 2020-07-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-02 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-10 | 開始されました | Canaccord Genuity | Buy |
| 2019-07-15 | 開始されました | Evercore ISI | Outperform |
| 2019-07-15 | 開始されました | JP Morgan | Overweight |
| 2019-07-15 | 開始されました | Jefferies | Buy |
| 2019-07-15 | 開始されました | ROTH Capital | Buy |
すべてを表示
Akero Therapeutics Inc (AKRO) 最新ニュース
Brokerages Set Akero Therapeutics, Inc. (NASDAQ:AKRO) PT at $46.83 - MarketBeat
H.C. Wainwright maintains buy on Akero stock - MSN
HC Wainwright Reiterates “Buy” Rating for Akero Therapeutics (NASDAQ:AKRO) - Defense World
Akero Therapeutics (NASDAQ:AKRO) Trading Up 8.4%Time to Buy? - MarketBeat
H.C. Wainwright maintains buy on Akero stock By Investing.com - Investing.com Canada
Akero Therapeutics (NASDAQ:AKRO) Given Buy Rating at HC Wainwright - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Stock Price Down 8.6%Should You Sell? - MarketBeat
(AKRO) Trading Report - Stock Traders Daily
Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 Synchrony Real-World Study Evaluating Efruxifermin in Patients with Non-Invasively Diagnosed Mash or MASLD - Marketscreener.com
Akero Therapeutics Completes Phase 3 SYNCHRONY Enrollment for Groundbreaking MASH Treatment - StockTitan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out - AccessWire
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Sold by JPMorgan Chase & Co. - Defense World
JPMorgan Chase & Co. Sells 54,221 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Investors to Learn More About the Investigation - AccessWire
Non-Alcoholic Steatohepatitis Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Madrigal Pharmac, Inventiva Pharma, Zydus Therapeutics, Novo Nordisk A/S, Viking - The Globe and Mail
Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Akero Therapeutics, Inc. (AKRO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Connect - AccessWire
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells 10,000 Shares of Stock - MarketBeat
Akero Therapeutics COO Jonathan Young sells $280,330 in stock By Investing.com - Investing.com Nigeria
Akero Therapeutics COO Jonathan Young sells $280,330 in stock - Investing.com
AKRO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces an Investigation into Akero Therapeutics, Inc. and Encourages Investors to Contact the Firm - AccessWire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Reach Out - AccessWire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Stockholders to Connect - AccessWire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation - AccessWire
Akero Therapeutics: Where This Potential MASH Play Stands Currently (NASDAQ:AKRO) - Seeking Alpha
2024-12-29 | Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Stockholders to Inquire about Securities Investigation | NDAQ:AKRO | Press Release - Stockhouse Publishing
Brokerages Set Akero Therapeutics, Inc. (NASDAQ:AKRO) Price Target at $46.83 - Defense World
Akero Therapeutics, Inc. (NASDAQ:AKRO) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Investors to Inquire about Securities Investigation - AccessWire
Geode Capital Management LLC Sells 48,027 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Geode Capital Management LLC Has $45.08 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Purchased by Barclays PLC - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Investors to Reach Out - AccessWire
Akero Therapeutics' senior VP Patrick Lamy sells $29,130 in stock By Investing.com - Investing.com Nigeria
Akero Therapeutics' senior VP Patrick Lamy sells $29,130 in stock - Investing.com India
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells 1,000 Shares of Stock - MarketBeat
Catriona Yale Sells 9,074 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat
Akero Therapeutics chief scientific officer sells $118,172 in stock By Investing.com - Investing.com South Africa
Akero Therapeutics executive sells $264k in stock By Investing.com - Investing.com Canada
Akero Therapeutics chief scientific officer sells $118,172 in stock - Investing.com
Akero Therapeutics (NASDAQ:AKRO) Trading Down 4.1%What's Next? - MarketBeat
State Street Corp Has $71.81 Million Stock Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Fmr LLC Acquires 26,691 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - Defense World
Fmr LLC Purchases 26,691 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat
Akero Therapeutics (NASDAQ:AKRO) Shares Up 3.5%Here's What Happened - MarketBeat
Short Interest in Akero Therapeutics, Inc. (NASDAQ:AKRO) Drops By 9.1% - Defense World
AKERO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc.AKRO - The Eastern Progress Online
Akero Therapeutics, Inc. (NASDAQ:AKRO) Short Interest Down 9.1% in November - MarketBeat
Akero Therapeutics Inc (AKRO) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):